|
 |
|
| |
SMi proudly present their 3rd annual COPD: Novel Therapeutics and Management Strategies conference to be held in Central London on Wednesday 19th and Thursday 20th of October 2011. Bringing together high level industry representatives as well as highly respected academic and medical figures, this is your opportunity to enjoy presentations on the latest hot topics surrounding COPD and to network with key industry professionals.
This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.
The conference agenda covers every phase of COPD study. We begin with a clinical perspective taking into account new targets for COPD and lessons that can be learned in future development and desgin. The most controversial of these novel therapeutics, roflumilast, is explored from a pharmacological and clinical perspective. This is followed with looks at combination and inhaled therapeutics.
The agenda focuses on discovery and devlopment from various interesting viewpoints, with pre and post clinical modelling and strategy addressed as well as Phase I & II studies.
|
|
Current Registered Attendess from the following companies include: Almirall, Argenta Discovery Ltd, Bayer Schering Pharma, Biomedical Systems Europe, Boehringer Ingelheim, Glaxosmithkline Biologicals, Grunenthal Gmb H, GSK, Hovione SA, Imperial College School of Medicine (N.H.L.I.), Johnson & Johnson, Kyorin Pharmaceutical Co Ltd, National Heart & Lung Institute, Nycomed GmbH, ProtAffin Biotechnologie AG, Revotar Biopharmaceuticals, Sandoz International Gmbh, Teva UK Limited, Vectura & Vitalograph Ltd
|